Grade C aGVHD

1 clinical trials · Condition

Record	Firm	Date
A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD) (NCT02336230)	Mesoblast, Inc.	2015-06-04

Every clearance here is in the API, with alerts when new ones post.